Efstathios Kastritis
#138,685
Most Influential Person Now
Researcher
Efstathios Kastritis's AcademicInfluence.com Rankings
Efstathios Kastritiscomputer-science Degrees
Computer Science
#6526
World Rank
#6879
Historical Rank
Computational Linguistics
#1146
World Rank
#1160
Historical Rank
Machine Learning
#2150
World Rank
#2178
Historical Rank
Artificial Intelligence
#2412
World Rank
#2453
Historical Rank
Download Badge
Computer Science
Efstathios Kastritis's Degrees
- Masters Artificial Intelligence University of Oxford
Similar Degrees You Can Earn
Why Is Efstathios Kastritis Influential?
(Suggest an Edit or Addition)Efstathios Kastritis's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. (2014) (2949)
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc (2011) (2474)
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. (2016) (1536)
- Hematological findings and complications of COVID‐19 (2020) (1325)
- Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. (2005) (1150)
- New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. (2012) (693)
- Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. (2009) (406)
- Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. (2006) (352)
- A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. (2013) (351)
- Organ-specific manifestations of COVID-19 infection (2020) (309)
- Diagnosis of monoclonal gammopathy of renal significance. (2015) (302)
- European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications (2015) (283)
- The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group (2018) (279)
- Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. (2010) (279)
- International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. (2016) (277)
- Pathogenesis and treatment of renal failure in multiple myeloma (2008) (269)
- How I treat monoclonal gammopathy of renal significance (MGRS). (2013) (254)
- Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia (2018) (244)
- Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study (2016) (235)
- Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop (2013) (216)
- Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. (2009) (199)
- Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG) (2009) (190)
- Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. (2017) (188)
- Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone (2007) (184)
- Emerging treatment strategies for COVID-19 infection (2020) (179)
- Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). (2013) (172)
- Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. (2007) (164)
- VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. (2009) (158)
- Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction post‐bortezomib monotherapy (2012) (155)
- Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. (2016) (153)
- Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease (2013) (140)
- Natural history of osteonecrosis of the jaw in patients with multiple myeloma. (2008) (140)
- Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications (2021) (138)
- The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma (2013) (138)
- Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. (2021) (135)
- Daratumumab Plus CyBorD for Patients With Newly Diagnosed AL Amyloidosis: Safety Run-in Results of ANDROMEDA. (2020) (133)
- Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. (2014) (127)
- Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies (2010) (122)
- Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. (2014) (110)
- Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors. (2009) (107)
- The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma (2014) (105)
- Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose (2021) (105)
- Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy. (2012) (103)
- Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study. (2019) (97)
- Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome (2017) (97)
- Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study. (2015) (95)
- Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups (2017) (94)
- Proteasome inhibitor associated thrombotic microangiopathy (2016) (90)
- The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment (2021) (90)
- International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM) (2020) (89)
- Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor–κB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton (2007) (88)
- Amyloid-beta (1-40) and the risk of death from cardiovascular causes in patients with coronary heart disease. (2015) (87)
- A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. (2012) (86)
- Cardiac and renal complications of carfilzomib in patients with multiple myeloma. (2017) (85)
- Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens (2008) (83)
- European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias (2018) (80)
- Recent advances in the management of AL Amyloidosis (2016) (80)
- Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: A single center experience on 228 patients (2012) (79)
- Central nervous system involvement by multiple myeloma: A multi‐institutional retrospective study of 172 patients in daily clinical practice (2016) (79)
- Epidemiology and organ specific sequelae of post-acute COVID19: A narrative review (2021) (77)
- Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. (2009) (76)
- The combination of gemcitabine and carboplatin as first‐line treatment in patients with advanced urothelial carcinoma (2006) (74)
- Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis. (2020) (73)
- Quantitative Diffusion-weighted Imaging of the Bone Marrow: An Adjunct Tool for the Diagnosis of a Diffuse MR Imaging Pattern in Patients with Multiple Myeloma. (2017) (72)
- Treatment of light chain deposition disease with bortezomib and dexamethasone (2009) (71)
- Bortezomib‐based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis (2016) (71)
- Treatment of relapsed/refractory multiple myeloma. (2009) (70)
- The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis (2008) (70)
- Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. (2020) (69)
- Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: a study by the Hellenic Cooperative Oncology Group. (2004) (69)
- Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma (2015) (69)
- The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy. (2005) (68)
- Treatment options for relapsed and refractory multiple myeloma. (2015) (68)
- Somatic mutations of adenomatous polyposis coli gene and nuclear b‐catenin accumulation have prognostic significance in invasive urothelial carcinomas: Evidence for Wnt pathway implication (2009) (66)
- Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration (2009) (66)
- Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment (2010) (66)
- A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis (2014) (64)
- Diffuse MRI marrow pattern correlates with increased angiogenesis, advanced disease features and poor prognosis in newly diagnosed myeloma treated with novel agents (2010) (60)
- Outpatient treatment of low‐risk neutropenic fever in cancer patients using oral moxifloxacin (2005) (60)
- Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration (2008) (58)
- Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin. (2019) (58)
- The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis (2008) (58)
- BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years. (2017) (57)
- Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH). (2009) (53)
- Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma (2014) (53)
- Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia (2016) (52)
- The evolving role of lenalidomide in the treatment of hematologic malignancies (2007) (52)
- Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia. (2019) (52)
- The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents. (2018) (51)
- Increased expression of macrophage inflammatory protein-1α on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma (2009) (51)
- Long‐term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies (2015) (51)
- Current treatments for renal failure due to multiple myeloma (2013) (50)
- Investigation and management of IgM and Waldenström‐associated peripheral neuropathies: recommendations from the IWWM‐8 consensus panel (2017) (49)
- Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis (2014) (49)
- Treatment of plasma cell dyscrasias with lenalidomide (2008) (47)
- Biweekly Carboplatin/Gemcitabine in Patients with Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: Report of Efficacy, Quality of Life and Geriatric Assessment (2008) (47)
- Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: A report of the Greek myeloma study group in 97 patients (2014) (46)
- Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy (2017) (45)
- Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem‐cell transplantation: Results of a single institution, randomized phase 2 trial (2010) (45)
- The International Prognostic Scoring System for Waldenström’s macroglobulinemia is applicable in patients treated with rituximab-based regimens (2008) (44)
- Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience (2015) (43)
- Targeted therapies in multiple myeloma (2009) (43)
- Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients (2021) (42)
- Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis. (2018) (41)
- How I treat Waldenström's Macroglobulinemia. (2019) (41)
- Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy (2015) (41)
- Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide‐based regimens (2013) (40)
- Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis (2022) (40)
- Increased serum lactate dehydrongenase should be included among the variables that define very-high-risk multiple myeloma. (2011) (39)
- A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome (2019) (38)
- Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis (2018) (38)
- Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL) (2019) (38)
- Novel approaches for reducing free light chains in patients with myeloma kidney (2012) (38)
- Multiple myeloma: Role of autologous transplantation. (2019) (38)
- The Chronic Kidney Disease Epidemiology Collaboration cystatin C (CKD‐EPI‐CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD‐EPI‐CysC equations? (2013) (38)
- Validation of the Criteria of Response to Treatment In AL Amyloidosis. (2010) (37)
- Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study (2021) (37)
- Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma. (2020) (36)
- The outcome of advanced or recurrent non-squamous carcinoma of the uterine cervix after platinum-based combination chemotherapy. (2005) (36)
- Patterns of pharmaceuticals use during the first wave of COVID-19 pandemic in Athens, Greece as revealed by wastewater-based epidemiology (2021) (36)
- Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study (2021) (36)
- Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ratio of angiopoietin‐1 to angiopoietin‐2 and angiogenin correlate with disease severity (2007) (35)
- Clinicopathological features of ovarian carcinosarcomas: a single institution experience. (2005) (35)
- Circulating angiopoietin‐1 to angiopoietin‐2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents (2012) (34)
- Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis. (2016) (34)
- Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers (2021) (33)
- Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies (2018) (33)
- COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network (2021) (32)
- Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents (2014) (32)
- The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: Final results on 205 patients of the Greek myeloma study group (2014) (32)
- The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective. (2016) (32)
- Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group (2018) (32)
- Treatment recommendations for patients with Waldenström's Macroglobulinemia (WM) and related disorders: consensus from the Seventh International Workshop on WM (2014) (31)
- A prospective study on lung toxicity in patients treated with gemcitabine and carboplatin: clinical, radiological and functional assessment. (2004) (31)
- Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens (2011) (31)
- VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT (2014) (31)
- Discovery and Optimization of a Selective Ligand for the Switch/Sucrose Nonfermenting-Related Bromodomains of Polybromo Protein-1 by the Use of Virtual Screening and Hydration Analysis (2016) (31)
- JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer. (2020) (31)
- Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes (2020) (30)
- Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study (2021) (30)
- Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies (2017) (30)
- Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone. (2019) (30)
- Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit (2017) (30)
- Increased angiogenesis and enhanced bone formation in patients with IgM monoclonal gammopathy and urticarial skin rash: new insight into the biology of Schnitzler syndrome (2012) (30)
- Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib (2016) (30)
- A revised international prognostic score system for Waldenström's macroglobulinemia. (2018) (30)
- Efficacy of Panobinostat for the Treatment of Multiple Myeloma (2020) (30)
- Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma (2013) (29)
- Sclerostin: a possible target for the management of cancer-induced bone disease (2012) (29)
- No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years (2011) (29)
- Multiple myeloma in octogenarians: Clinical features and outcome in the novel agent era (2012) (29)
- Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report (2020) (29)
- The outcome of patients with advanced pure squamous or mixed squamous and transitional urothelial carcinomas following platinum-based chemotherapy. (2006) (29)
- Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment. (2005) (28)
- A revised international prognostic score system for Waldenström’s macroglobulinemia (2019) (28)
- Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine (2021) (28)
- Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens (2017) (27)
- Prognostication in young and old patients with Waldenström's macroglobulinemia: importance of the International Prognostic Scoring System and of serum lactate dehydrogenase. (2009) (27)
- Response to bortezomib of a patient with scleromyxedema refractory to other therapies. (2011) (27)
- Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review. (2018) (27)
- Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events (2017) (27)
- Emerging antibodies for the treatment of multiple myeloma (2016) (26)
- The Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Multiple Myeloma Who Receive Biphosphonates Depends on the Type of Biphosphonate. (2005) (26)
- Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection (2020) (26)
- Brain metastases as isolated site of relapse in patients with epithelial ovarian cancer previously treated with platinum and paclitaxel‐based chemotherapy (2006) (26)
- Abnormal bone remodelling and increased levels of macrophage inflammatory protein‐1 alpha (MIP‐1α) in Waldenström macroglobulinaemia (2006) (25)
- Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma (2018) (25)
- Prognostic factors for multiple myeloma in the era of novel therapies (2018) (25)
- Toll-Like Receptor 4 Activation Promotes Multiple Myeloma Cell Growth and Survival Via Suppression of The Endoplasmic Reticulum Stress Factor Chop (2019) (24)
- High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents. (2010) (24)
- Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines (2021) (24)
- Ibrutinib Treatment in Waldenström's Macroglobulinemia: Follow-up Efficacy and Safety from the iNNOVATETM Study (2018) (24)
- Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients (2019) (23)
- Mantle-cell lymphoma (multiple lymphomatous polyposis) of the entire GI tract. (2008) (23)
- Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells (2012) (23)
- The impact of age in the outcome of patients with advanced or recurrent cervical cancer after platinum-based chemotherapy. (2007) (23)
- Primary Treatment of Waldenstrom's Macroglobulinemia with Dexamethasone, Rituximab and Cyclophosphamide (DRC): Final Analysis of a Phase II Study (2012) (23)
- Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma (2020) (22)
- A randomized phase 3 study of ixazomib–dexamethasone versus physician’s choice in relapsed or refractory AL amyloidosis (2021) (22)
- Reactive Vasodilation Predicts Mortality in Primary Systemic Light-Chain Amyloidosis (2019) (22)
- Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals (2021) (22)
- Updated risk stratification model for smoldering multiple myeloma (SMM) incorporating the revised IMWG diagnostic criteria. (2019) (22)
- Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome. (2021) (21)
- The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients' renal function. (2010) (21)
- Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (21)
- A phase II study of capecitabine plus oxaliplatin (XELOX) (2005) (21)
- Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study (2018) (21)
- Conservative Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw in Multiple Myeloma Patients (2014) (21)
- High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events (2021) (21)
- The Combination of Bortezomib, Melphalan, Dexamethasone and Intermittent Thalidomide (VMDT) Is an Effective Treatment for Relapsed/Refractory Myeloma: Results of a Phase II Clinical Trial. (2005) (21)
- An overview of the role of carfilzomib in the treatment of multiple myeloma (2017) (20)
- Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents (2015) (20)
- A review of the venous thrombotic issues associated with multiple myeloma (2016) (20)
- Young Age Is Associated with Favorable Characteristics but Is Not an Independent Prognostic Factor in Patients with Epithelial Ovarian Cancer: A Single Institution Experience (2006) (20)
- Bortezomib as a treatment option in patients with Waldenström macroglobulinemia. (2010) (20)
- Next generation flow cytometry for MRD detection in patients with AL amyloidosis (2020) (20)
- Current treatments for renal failure due to multiple myeloma (2013) (19)
- Systemic Chemotherapy with Pemetrexed and Cisplatin for Malignant Peritoneal Mesothelioma: A Single Institution Experience (2011) (19)
- Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis (2017) (19)
- Bortezomib for AL amyloidosis: moving forward. (2011) (19)
- Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p (2018) (18)
- Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group. (2005) (18)
- Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma (2020) (18)
- Five-Year Follow-Up of Ibrutinib Plus Rituximab Vs Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase 3 iNNOVATETM Study (2020) (18)
- The Combination of Bortezomib, Melphalan, Dexamethasone and Intermittent Thalidomide (VMDT) Is an Effective Regimen for Relapsed/Refractory Myeloma and Reduces Serum Levels of Dickkopf-1, RANKL, MIP-1α and Angiogenic Cytokines. (2006) (18)
- Economic evaluation of therapies for patients suffering from relapsed-refractory multiple myeloma in Greece (2013) (17)
- Angiogenetic factors and biochemical markers of bone metabolism in POEMS syndrome treated with high-dose therapy and autologous stem cell support. (2006) (17)
- Cytogenetics and Survival of Multiple Myeloma: Isolated and Combined Effects. (2016) (17)
- Carboplatin Hypersensitivity Reactions: A Single Institution Experience (2005) (17)
- Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy (2014) (17)
- Advanced epithelial ovarian cancer in the elderly: chemotherapy tolerance and outcome. (2007) (17)
- Myeloma patients with COVID‐19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine (2021) (16)
- Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma (2019) (16)
- Neutrophil Gelatinase--Associated Lipocalin and Cystatin C Are Sensitive Markers of Renal Injury in Patients With Multiple Myeloma. (2016) (16)
- Intramedullary spinal cord and leptomeningeal metastases in a patient with carcinoma of the uterine cervix. (2006) (16)
- Lenalidomide‐associated pneumonitis in patients with plasma cell dyscrasias (2011) (16)
- Evaluation of the Prognostic and Predictive Value of HER-1/EGFR in Breast Cancer Patients Participating in a Randomized Study with Dose-Dense Sequential Adjuvant Chemotherapy (2008) (16)
- High levels of periostin correlate with increased fracture rate, diffuse MRI pattern, abnormal bone remodeling and advanced disease stage in patients with newly diagnosed symptomatic multiple myeloma (2016) (16)
- Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment (2016) (15)
- Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates (2019) (15)
- Ex Vivo Models Simulating the Bone Marrow Environment and Predicting Response to Therapy in Multiple Myeloma (2020) (15)
- Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy (2022) (15)
- Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis (2020) (15)
- Significant reduction in the visits to the emergency room department during the COVID-19 pandemic in a tertiary hospital in Greece (2020) (14)
- Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (14)
- Systemic AL Amyloidosis: Current Approaches to Diagnosis and Management (2020) (14)
- Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals (2021) (14)
- Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo staging (2015) (14)
- Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222 (2022) (14)
- Evaluating ibrutinib in the treatment of symptomatic Waldenstrom’s macroglobulinemia (2019) (14)
- Rituximab-based treatments in Waldenström's macroglobulinemia. (2009) (14)
- SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors (2021) (14)
- Current treatment options and investigational drugs for Waldenstrom’s Macroglobulinemia (2017) (14)
- Pulsed cyclophosphamide, thalidomide and dexamethasone regimen for previously treated patients with multiple myeloma: Long term follow up and disease control after subsequent treatments (2007) (14)
- Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients (2020) (14)
- Treatment of Relapsed/Refractory Multiple Myeloma with Thalidomide-based Regimens: Identification of Prognostic Factors (2004) (14)
- Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy (2019) (13)
- Renal Failure in Multiple Myeloma: Incidence, Correlations and Prognostic Significance. (2006) (13)
- Long-Term Follow-Up of Multiple Myeloma (MM) Patients (pts) with Osteonecrosis of the Jaw (ONJ). (2007) (13)
- Schnitzler's syndrome: increased levels of bone formation and angiogenesis factors are reduced after successful pefloxacin treatment. (2008) (13)
- Clinical characteristics and outcome of primary systemic light-chain amyloidosis in Greece. (2010) (13)
- Recovery of Innate Immune Cells and Persisting Alterations in Adaptive Immunity in the Peripheral Blood of Convalescent Plasma Donors at Eight Months Post SARS-CoV-2 Infection (2021) (13)
- Proteasome Inhibitors in Waldenström Macroglobulinemia. (2018) (13)
- Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome (2020) (13)
- A European Collaborative Study of Treatment Outcomes In 428 Patients with Systemic AL Amyloidosis (2010) (13)
- Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID‐19 pandemic (2020) (13)
- Managing renal complications in multiple myeloma (2016) (13)
- Clinical Features, Outcome and Prognostic Factors For Survival and Evolution To Multiple Myeloma Of Solitary Plasmacytomas: A Report Of The Greek Myeloma Study Group In 97 Patients (2013) (12)
- Primary failure of bortezomib in newly diagnosed multiple myeloma – understanding the magnitude, predictors, and significance (2016) (12)
- Acalabrutinib in patients (pts) with Waldenström macroglobulinemia (WM). (2018) (12)
- Subcutaneous daratumumab (DARA SC) plus cyclophosphamide, bortezomib, and dexamethasone (CyBorD) in patients (Pts) with newly diagnosed amyloid light chain (AL) amyloidosis: Safety run-in results of andromeda. (2018) (12)
- Prevention and Treatment of Myeloma Bone Disease (2012) (12)
- European Collaborative Study of Treatment Outcomes in 347 Patients with Systemic AL Amyloidosis with Mayo Stage III Disease (2011) (12)
- Emerging treatment approaches for myeloma-related bone disease (2017) (12)
- Bortezomib in Combination with Dexamethasone, Rituximab and Cyclophosphamide (B-DRC) As First - Line Treatment of Waldenstrom's Macroglobulinemia: Results of a Prospectively Randomized Multicenter European Phase II Trial (2020) (11)
- The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma (2020) (11)
- Expression of CCL3 by neoplastic cells in patients with Waldenström's macroglobulinemia: an immunohistochemical study in bone marrow biopsies of 67 patients. (2011) (11)
- Microvessel density (MVD) and cyclooxygenase-2 (COX-2)/ beta-catenin interaction are associated with relapse in patients with transitional carcinoma receiving adjuvant chemotherapy with paclitaxel/carboplatin: a hellenic cooperative oncology group (HECOG) study. (2008) (11)
- High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients (2010) (11)
- Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone. (2019) (11)
- Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study (2021) (11)
- Non-secretory myeloma: one, two, or more entities? (2013) (11)
- Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myeloma (2018) (11)
- Angiogenesis in Waldenström's macroglobulinemia. (2009) (10)
- A Phase I/II Study of Lenalidomide (R) with Low Dose Dexamethasone (d) and Cyclophosphamide (C) for Patients with Primary Systemic (AL) Amyloidosis. (2009) (10)
- Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics (2015) (10)
- Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study (2021) (10)
- Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström’s macroglobulinemia (2017) (10)
- Pomalidomide and dexamethasone (pom-dex) with or without daratumumab (DARA) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): A multicenter, randomized, phase 3 study (APOLLO). (2018) (10)
- Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents (2020) (10)
- Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma (2019) (10)
- First Glimpse on Real-World Efficacy Outcomes for 2000 Patients with Systemic Light Chain Amyloidosis in Europe: A Retrospective Observational Multicenter Study By the European Myeloma Network (2020) (10)
- Daratumumab‐based therapy for patients with monoclonal gammopathy of renal significance (2020) (10)
- SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response (2021) (10)
- Circulating Levels of the Wnt Inhibitors Dickkopf-1 and Sclerostin In Different Phases of Multiple Myeloma: Alterations Post-Therapy with Lenalidomide and Dexamethasone with or without Bortezomib (2010) (10)
- How We Manage Patients with Plasmacytomas (2018) (10)
- A phase I-II trial of gefitinib in combination with vinorelbine and oxaliplatin as salvage therapy in women with advanced ovarian cancer (AOC) (2004) (10)
- Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patients (2019) (10)
- Molecular responses to therapeutic proteasome inhibitors in multiple myeloma patients are donor-, cell type- and drug-dependent (2018) (9)
- Subcutaneous daratumumab + bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis: Updated results from the phase 3 ANDROMEDA study. (2021) (9)
- Cystatin-C Is a Sensitive Marker of Renal Impairment with an Independent Predictive Value for Survival in Multiple Myeloma; Reduction Post Bortezomib Monotherapy. (2007) (9)
- A Molecular Signature of Circulating MicroRNA Can Predict Osteolytic Bone Disease in Multiple Myeloma (2021) (9)
- Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients (2021) (9)
- Hematological malignancies: myeloma. (2006) (9)
- Significant Activity of Bortezomib-Based Therapy in Patients with Primary Systemic (AL) Amyloidosis (2008) (9)
- Emerging Insights Into the Role of the Hippo Pathway in Multiple Myeloma and Associated Bone Disease. (2019) (9)
- Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2019) (9)
- Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma (2019) (9)
- Bone marrow biopsy in low‐risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group (2019) (9)
- Immunogenic Cell Death, DAMPs and Prothymosin α as a Putative Anticancer Immune Response Biomarker (2022) (9)
- Publisher Correction: The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group (2018) (9)
- Cell‐free DNA analysis for the detection of MYD88 and CXCR4 mutations in IgM monoclonal gammopathies; an update with clinicopathological correlations (2020) (9)
- Early Relapse After Autologous Transplant Is Associated With Very Poor Survival and Identifies an Ultra-High-Risk Group of Patients With Myeloma. (2020) (9)
- Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group (2022) (9)
- Increased expression of cyclin‐D1 on trephine bone marrow biopsies independently predicts for shorter overall survival in patients with multiple myeloma treated with novel agents (2012) (9)
- High Serum Sclerostin Correlates with Advanced Stage, Increased Bone Resorption, Reduced Osteoblast Function, and Poor Survival in Newly-Diagnosed Patients with Multiple Myeloma. (2009) (9)
- A phase I-II trial of gefitinib in combination with vinorelbine and oxaliplatin as salvage therapy in women with advanced ovarian cancer (AOC). (2004) (9)
- The Addition of Bortezomib to the Combination of Lenalidomide and Dexamethasone Increases Bone Formation in Relapsed/Refractory Myeloma: a Prospective Study in 91 Patients. (2009) (9)
- "Real World" Data on the Efficacy and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Combined Study from the Greek, Czech and UK Databases (2017) (9)
- Low Spike Antibody Levels and Impaired BA.4/5 Neutralization in Patients with Multiple Myeloma or Waldenstrom’s Macroglobulinemia after BNT162b2 Booster Vaccination (2022) (9)
- Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic (2020) (8)
- Bortezomib–Melphalan–Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients with Impaired Renal Function: Cohort Analysis of the Phase III VISTA Study. (2008) (8)
- Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity (2015) (8)
- Short progression‐free survival predicts for poor overall survival in older patients with multiple myeloma treated upfront with novel agent‐based therapy (2011) (8)
- Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcome (2019) (8)
- Involvement of small nerve fibres and autonomic nervous system in AL amyloidosis: comprehensive characteristics and clinical implications (2020) (8)
- Decreased Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Multiple Myeloma (MM) Treated with Zoledronic Acid (ZA) after Application of Preventive Measures. (2007) (8)
- SARS‐CoV‐2 humoral responses following booster BNT162b2 vaccination in patients with B‐cell malignancies (2022) (8)
- Second Booster BNT162b2 Restores SARS-CoV-2 Humoral Response in Patients With Multiple Myeloma, Excluding Those Under Anti-BCMA Therapy (2022) (8)
- A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options (2019) (8)
- How I treat elderly patients with plasma cell dyscrasias (2018) (8)
- Kinetics of Anti-Sars-Cov-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers (2021) (8)
- Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study (2020) (8)
- Prognosis and risk assessment in AL amyloidosis – state of the art (2011) (8)
- miRNA-seq and clinical evaluation in multiple myeloma: miR-181a overexpression predicts short-term disease progression and poor post-treatment outcome (2021) (8)
- Blood Transcriptomes of Anti-SARS-CoV-2 Antibody-Positive Healthy Individuals Who Experienced Asymptomatic Versus Clinical Infection (2021) (8)
- Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib (2020) (8)
- Solid Organ Transplantation in Amyloidosis (2020) (8)
- S875 SUBCUTANEOUS DARATUMUMAB + CYCLOPHOSPHAMIDE, BORTEZOMIB, AND DEXAMETHASONE (CYBORD) IN PATIENTS WITH NEWLY DIAGNOSED AMYLOID LIGHT CHAIN (AL) AMYLOIDOSIS: UPDATED SAFETY RUN-IN RESULTS OF ANDROMEDA (2019) (8)
- Ixazomib, Rituximab and Dexamethasone (IRD) in Patients with Relapsed or Progressive Waldenstrom's Macroblobulinemia: Results of the Prospective Phase I/II HOVON 124/Ecwm-R2 Trial (2019) (8)
- Management of relapsed and relapsed refractory myeloma. (2007) (8)
- TLR4/TIRAP polymorphisms are associated with progression and survival of patients with symptomatic myeloma (2016) (7)
- Ixazomib-dexamethasone (Ixa-Dex) vs physician’s choice (PC) in relapsed/refractory (RR) primary systemic AL amyloidosis (AL) patients (pts) by prior proteasome inhibitor (PI) exposure in the phase III TOURMALINE-AL1 trial. (2020) (7)
- An update on the use of lenalidomide for the treatment of multiple myeloma (2015) (7)
- Emerging drugs for Waldenström's macroglobulinemia (2011) (7)
- Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis (2021) (7)
- Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma (2019) (7)
- Diffusion-Weighted Imaging Improves Accuracy in the Diagnosis of MRI Patterns of Marrow Involvement in Newly Diagnosed Myeloma: Results of a Prospective Study in 99 Patients (2015) (7)
- Treatment of Bing–Neel syndrome with first line sequential chemoimmunotherapy (2019) (7)
- Adjuvant chemotherapy with paclitaxel and carboplatin in non-endometrioid carcinoma of the uterus. (2005) (7)
- The role of novel drugs in multiple myeloma. (2008) (7)
- Tubular Damage Is Ubiquitous in Newly-Diagnosed Patients with Multiple Myeloma: Comparison of Three Urinary and Two Serum Markers of Kidney Injury. (2012) (7)
- Antibody Response After Initial Vaccination for SARS-CoV-2 in Patients With Amyloidosis (2021) (7)
- Overweight/Obesity and Monoclonal Gammopathy of Undetermined Significance. (2021) (7)
- Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors (2021) (7)
- Primary Therapy of Waldenström's Macroglobulinemia (WM) with Weekly Bortezomib, Low-Dose Dexamethasone and Rituximab (BDR): A Phase II Study of the European Myeloma Network (2009) (7)
- How I Treat Relapsed Multiple Myeloma. (2022) (7)
- Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period (2020) (7)
- Myeloma in the Octogenarians: Disease Characteristics and Clinical Outcomes in the Era of Modern Anti-Myeloma Therapy (2014) (7)
- Hematologic response and stabilization of renal function in a patient with light chain deposition disease after lenalidomide treatment: a novel therapeutic approach? (2014) (7)
- Monitoring Plasma Cell Dyscrasias With Cell-free DNA Analysis. (2020) (7)
- Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (6)
- Determination of MYD88L265P mutation fraction in IgM monoclonal gammopathies (2021) (6)
- Efficacy and safety of elotuzumab for the treatment of multiple myeloma (2017) (6)
- Very Early Death (<2 months) In Myeloma Is Associated With Advanced Age, Poor Performance Status and Reduced Use Of Novel Agents, While Early Death Within 12 Months Is Associated With High Risk Features Of Both The Disease and The Patient (2013) (6)
- Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study (2021) (6)
- Proteasome inhibitor therapy for Waldenström's macroglobulinemia. (2013) (6)
- Is there still place for VAD as primary treatment for patients with multiple myeloma who are candidates for high-dose therapy? (2006) (6)
- How I treat rituximab refractory patients with WM (2018) (6)
- Birtamimab in patients with Mayo stage IV AL amyloidosis: Rationale for confirmatory affirm-AL phase 3 study. (2022) (6)
- Glomerular expression of matrix metalloproteinases in AL-amyloidosis and association with renal function at the time of kidney biopsy. (2016) (6)
- Anthracycline-based adjuvant chemotherapy in early-stage uterine sarcomas: long-term results of a single institution experience. (2007) (6)
- Treatment of Patients with Relapsed/Refractory Multiple Myeloma (MM) with Lenalidomide and Dexamethasone with or without Bortezomib: Prospective Evaluation of the Impact of Cytogenetic Abnormalities. (2009) (6)
- Serum free immunoglobulin light chain fingerprint identifies a subset of newly diagnosed multiple myeloma patients with worse outcome (2017) (6)
- Occupational Exposure and Multiple Myeloma Risk: An Updated Review of Meta-Analyses (2021) (6)
- Outcomes By Cardiac Stage in Newly Diagnosed AL Amyloidosis: Results from Andromeda (2020) (6)
- The Role of Novel Agents on Reversibility of Renal Impairment in Newly Diagnosed Patients with Multiple Myeloma; a Single Center Experience on 112 Patients, (2011) (6)
- Growth Differentiation Factor-15 (GDF-15) Is a New Biomarker with Independent Prognostic Significance for Survival and Renal Outcomes in Different Cohorts of Patients with Light Chain (AL) Amyloidosis (2016) (5)
- When a little aspirin may be enough. (2012) (5)
- Cardiac amyloidosis: in search of the ideal diagnostic tool (2019) (5)
- Systemic Light Chain Amyloidosis across Europe: Key Outcomes from a Retrospective Study of 4500 Patients (2021) (5)
- The utility of splenic imaging parameters in cardiac magnetic resonance for the diagnosis of immunoglobulin light-chain amyloidosis (2022) (5)
- Evaluation of pre-mir-34a rs72631823 single nucleotide polymorphism in triple negative breast cancer: A case-control study (2018) (5)
- Current therapy guidelines for Waldenstrom's macroglobulinaemia. (2016) (5)
- 1035TiPA multicenter, randomized, phase 3 study of pomalidomide and dexamethasone (Pom-dex) with or without daratumumab in patients with relapsed or refractory multiple myeloma (RRMM): APOLLO (2017) (5)
- How to prevent deep vein thrombosis in myeloma patients receiving thalidomide or lenalidomide (2007) (5)
- OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis (2019) (5)
- The Combination of Bortezomib, Doxorubicin, and Dexamethasone (PAD) Is an Effective Regimen for High Risk, Newly Diagnosed, Patients with Multiple Myeloma, Reduces Bone Resorption and Normalizes Angiopoietin-1 to Angiopoietin-2 Ratio. (2007) (5)
- A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome (2021) (5)
- Consolidation with a short course of daratumumab in patients with AL amyloidosis or light chain deposition disease (2021) (5)
- Semaphorin-4D and Plexin-B1 Are Elevated in Multiple Myeloma Microenvironment and Possibly Contribute in the Development of Lytic Bone Disease (2012) (5)
- Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C‐C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia (2018) (5)
- The Combination of the Proteasome Inhibitor Bortezomib with Doxorubicin and Dexamethasone (PAD Regimen) as Front-Line Therapy In Newly Diagnosed, High-Risk Multiple Myeloma: Results of a Phase II Prospective Multicenter Study (2010) (5)
- A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (2021) (5)
- Growth Differentiation Factor-15 in Patients with Light Chain (AL) Amyloidosis Has Independent Prognostic Significance and Adds Prognostic Information Related to Risk of Early Death and Renal Outcomes (2014) (5)
- Thalidomide plus dexamethasone as primary therapy for newly diagnosed patients with multiple myeloma (2008) (5)
- Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: Results on Efficacy and Safety of the Phase 2 Dare Study (2020) (5)
- Aberrant Plasma Cell Contamination of Peripheral Blood Stem Cell Autografts, Assessed by Next-Generation Flow Cytometry, Is a Negative Predictor for Deep Response Post Autologous Transplantation in Multiple Myeloma; A Prospective Study in 199 Patients (2021) (5)
- Thalidomide in the treatment of multiple myeloma. (2007) (5)
- Long Term Follow up of the Combination of Bortezomib with Dexamethasone as Initial Treatment for AL Amyloidosis (2010) (5)
- Outcomes of patients with t(11;14) multiple myeloma: An International Myeloma Working Group (IMWG) multicenter study. (2019) (5)
- Next Generation Flow Cytometry Provides a Standardized, Highly Sensitive and Informative Method for the Analysis of Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma: A Single Center Study in 182 Patients (2019) (4)
- The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients' renal function. (2012) (4)
- Real-World Data on Incidence, Clinical Characteristics and Outcome of Patients with Macrofocal Multiple Myeloma (MFMM) in the Era of Novel Therapies: A Study of the Greco-Israeli Collaborative Myeloma Working Group (2018) (4)
- The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies (2017) (4)
- Whole-Body Low-Dose CT in Multiple Myeloma: Diagnostic Value of Appendicular Medullary Patterns of Attenuation. (2021) (4)
- Frequency and Prognostic Significance of Hypercalcemia in Patients with Multiple Myeloma: An Analysis of the Database of the Greek Myeloma Study Group (2011) (4)
- Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional cases (2018) (4)
- Elevated Levels of Circulating Activin-A Correlate with Features of Advanced Disease, Extensive Bone Involvement and Inferior Survival In Patients with Multiple Myeloma (2010) (4)
- Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group (2018) (4)
- Exercise-Induced Changes in Tumor Growth via Tumor Immunity (2021) (4)
- Skeletal-Related Events In Patients With Multiple Myeloma In The Era Of Novel Agents: Low Incidence Of Pathological Fractures After Treatment (2013) (4)
- Population Pharmacokinetics and Exposure‐Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light‐Chain Amyloidosis (2021) (4)
- Corrections to "Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". (2018) (4)
- The Cytogenetic Profile of Primary and Secondary Plasma Cell Leukemia: Etiopathogenetic Perspectives, Prognostic Impact and Clinical Relevance to Newly Diagnosed Multiple Myeloma with Differential Circulating Clonal Plasma Cells (2022) (4)
- Erratum: Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (Annals of oncology : official journal of the European Society for Medical Oncology (2018) 29 Suppl 4 (iv41-iv50)) (2018) (4)
- Comparison of MRI Features of Fat Fraction and ADC for Early Treatment Response Assessment in Participants with Multiple Myeloma. (2022) (4)
- Rare manifestations of extramedullary myeloma: testicular plasmacytomas (2018) (4)
- A prognostic index predicting survival in transformed Waldenström macroglobulinemia (2020) (4)
- Rapid and Deep Hematologic Responses Are Associated with Improved Major Organ Deterioration Progression-Free Survival in Newly Diagnosed AL Amyloidosis: Results from Andromeda (2020) (4)
- Bendamustine rituximab (BR) versus ibrutinib (Ibr) as primary therapy for Waldenström macroglobulinemia (WM): An international collaborative study. (2022) (4)
- Dynamic contrast-enhanced magnetic resonance imaging parameters correlate with advanced revised-ISS and angiopoietin-1/angiopoietin-2 ratio in patients with multiple myeloma (2017) (4)
- Improved Survival of Patients with Multiple Myeloma after the Introduction of Novel Agents and the Applicability of the International Staging System (ISS) An Analysis of the Greek Myeloma Study Group (GMSG) (2008) (4)
- Appraising myc involvement in high risk myeloma (2015) (4)
- Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival (2021) (4)
- Disease control should be the goal of therapy for WM patients. (2017) (4)
- Graded Renal Response Criteria for Light Chain (AL) Amyloidosis (2021) (4)
- Prognosis and risk assessment in AL amyloidosis – There and back again (2017) (4)
- Plasma Metabolomic Alterations Induced by COVID-19 Vaccination Reveal Putative Biomarkers Reflecting the Immune Response (2022) (4)
- Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications (2021) (3)
- Genetic and Functional Evidence of Complement Dysregulation in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy Compared to Controls (2022) (3)
- tRNA Derivatives in Multiple Myeloma: Investigation of the Potential Value of a tRNA-Derived Molecular Signature (2021) (3)
- Elevated Serum Lactate Dehydrogenase (LDH) Should Be Included Among the Variables Which Define High Risk Multiple myeloma (2010) (3)
- Non‐lethal proteasome inhibition activates pro‐tumorigenic pathways in multiple myeloma cells (2019) (3)
- Daratumumab combinations: what can we learn? (2017) (3)
- Early Relapse Post Autologous Transplantation Is Associated with Very Poor Survival and Identifies an Ultra High Risk Group of Myeloma Patients (2017) (3)
- Kinetics of anti‐SARS‐CoV‐2 neutralizing antibodies development after BNT162b2 vaccination in patients with amyloidosis and the impact of therapy (2021) (3)
- Reversibility of Renal Impairment of Multiple Myeloma Patients Treated with Bortezomib-Based Regimens: Identification of Predictive Factors. (2008) (3)
- Biomarkers in AL Amyloidosis (2021) (3)
- Early tumor-cell gene expression changes may predict the response to first-line bortezomib-based therapy in patients with newly diagnosed multiple myeloma. (2015) (3)
- Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia. (2023) (3)
- The Addition of IMiDs for Patients with Daratumumab-Refractory Multiple Myeloma Can Overcome Refractoriness to Both Agents (2020) (3)
- Daratumumab May Attenuate Cardiac Dysfunction Related to Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma: A Prospective Study (2021) (3)
- Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy (2021) (3)
- The Interaction of Bortezomib with P-Gp, MRP-1 and BCRP Drug Transporters: Implications for Therapeutic Applications of Bortezomib in Advanced Multiple Myeloma and Other Neoplasias. (2009) (3)
- Carfilzomib for treating myeloma (2016) (3)
- Subcutaneous Daratumumab (DARA SC) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Asian Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Subgroup Analysis from the Phase 3 Andromeda Study (2020) (3)
- Randomized phase 3 trial of ibrutinib/rituximab vs placebo/rituximab in Waldenström's macroglobulinemia. (2018) (3)
- Outcomes after Initial Relapse of Multiple Myeloma: An International Myeloma Working Group Study (2015) (3)
- Continuing Cancer Therapy through the Pandemic While Protecting Our Patients: Results of the Implementation of Preventive Strategies in a Referral Oncology Unit (2021) (3)
- Hypercalcemia Remains an Adverse Prognostic Factor for Newly Diagnosed Patients with Symptomatic Multiple Myeloma in the Era of Novel Anti-Myeloma Therapies, Independently of Age, ISS Stage and Treatment Type: An Analysis of 2129 Patients (2014) (3)
- Outcome of patients with advanced non-transitional urothelial carcinomas following platinum-based chemotherapy (2005) (3)
- Treatment of Patients with Multiple Myeloma Complicated by Renal Failure with Bortezomib - Based Regimens. (2007) (3)
- The Spectrum of Ocular Manifestations in Patients with Waldenström’s Macroglobulinemia (2021) (3)
- Clinical Features and Outcome of Newly Diagnosed, Symptomatic Patients with Multiple Myeloma ≥80 Years of Age: An Analysis of the Greek Myeloma Study Group (2011) (3)
- Consolidation Therapy with Bortezomib, Thalidomide and Dexamethasone (VTD) Regimen After ASCT in Myeloma Patients Who Do Not Receive Bisphosphonates Reduces Bone Resorption and RANKL/OPG Ratio but Seems to Have No Effect On Bone Formation and Angiogenesis. (2009) (3)
- Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma (2016) (3)
- Next Generation Flow (NGF) Cytometry for Minimal Residual Disease (MRD) Evaluation in Multiple Myeloma (MM) Patients with Sustained Complete Response (CR) after Frontline Therapy: Results of a Prospective Single-Center Analysis (2017) (3)
- Three Drug Combinations Based on Bortezomib and Dexamethasone (VD) Backbone Improve Renal Function More Efficiently Than VD in Myeloma Patients with Severe Renal Impairment (2014) (3)
- Treatment of Light Chain (AL) Amyloidosis and Light Chain Deposition Disease (LCDD) with the Combination of Bortezomib and Dexamethasone. (2007) (3)
- Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study (2021) (3)
- Renal Impairment Is Not An Independent Adverse Prognostic Factor In Multiple Myeloma Patients Who Are Treated Upfront with Novel Agent-Based Regimens (2010) (3)
- Treatment of Patients with Relapsed/Refractory Multiple Myeloma (MM) with Lenalidomide and Dexamethasone with or with Bortezomib Depending on Prior Neurotoxicity: Prospective Evaluation of the Impact of Cytogenetic Abnormalities and Assessment of Bone Met. (2008) (3)
- Impact of Daratumumab-Containing Induction on Stem Cell Mobilization and Collection, Engraftment and Hospitalization Parameters Among Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation (2021) (3)
- A Cancer-Related microRNA Signature Shows Biomarker Utility in Multiple Myeloma (2021) (3)
- Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM. (2019) (3)
- Denosumab for myeloma bone disease: ready for prime time? (2018) (3)
- The Role of Angiopoietins System in Waldenstrom's Macroglobulinemia: Correlations with Marrow Microvessel Density and Survival (2012) (3)
- Central Nervous System Involvement by Multiple Myeloma: a Multi-Institutional Retrospective Study of 172 Patients (2015) (2)
- The Novel Proteasome Inhibitors Carfilzomib and Oprozomib Induce Milder Degenerative Effects Compared To Bortezomib When Administered Via Oral Feeding In An In Vivo Drosophila Experimental Model: A Biological Platform To Evaluate Safety/Efficacy Of Proteasome Inhibitors (2013) (2)
- A Molecular Signature of Three tRNA-Derived RNA Fragments May Discriminate Smoldering from Symptomatic Multiple Myeloma Patients (2019) (2)
- Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis (2021) (2)
- Hereditary systemic amyloidosis caused by K19T apolipoprotein C-II variant (2019) (2)
- Increased Angiogenesis and Enhanced Bone Formation in Patients with IgM Monoclonal Gammopathy and Urticarial Skin Rash: New Insight Into the Biology of the Schnitzler Syndrome (2011) (2)
- Diffuse Medullary Hyperdensities of the Femora and Humeri on Whole-Body Low-Dose Computed Tomography Identify Diffuse MRI Pattern of Involvement and Correlate with Advanced Disease Stage in Patients with Multiple Myeloma (2017) (2)
- Predictive Factors for Neutralizing Antibody Levels Nine Months after Full Vaccination with BNT162b2: Results of a Machine Learning Analysis (2022) (2)
- Future Developments in the Treatment of AL Amyloidosis (2022) (2)
- Correction to: "Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". (2019) (2)
- No Survival Improvement for Central Nervous System Multiple Myeloma By the Use of Novel Anti-Myeloma Agents: The Greek Myeloma Study Group Experience (2014) (2)
- Progression risk stratification of Asymptomatic Waldenström Macroglobulinemia (2019) (2)
- Autophagy activation can partially rescue proteasome dysfunction‐mediated cardiac toxicity (2022) (2)
- PS1392 CONSOLIDATION WITH A SHORT COURSE OF DARATUMUMAB CAN SIGNIFICANTLY IMPROVE COMPLETE RESPONSE RATES IN PATIENTS WITH AL AMYLOIDOSIS OR LCDD (2019) (2)
- Thrombotic Microangiopathy in Multiple Myeloma (2015) (2)
- Screening for Gaucher disease among patients with plasma cell dyscrasias (2019) (2)
- Managing myeloma with limited resources in the era of novel drugs (2018) (2)
- Reversibility of Renal Failure in Newly Diagnosed Patients with Multiple Myeloma Treated with High-Dose Dexamethasone Containing Regimens and the Impact of Novel Agents. (2006) (2)
- Carfilzomib-Associated Renal Toxicity Is Common and Unpredictable: An Analysis of 114 Patients (2018) (2)
- Patients with POEMS Syndrome Have High Bone Turnover and Increased Circulating Angiogenic Cytokines; Should Angiopoietin-2 and Bone-Specific Alkaline Phosphatase Be Used As Minor Criteria for the Diagnosis of the Disease? (2011) (2)
- Elevated Von Willebrand Factor Antigen Serum Levels Are Associated With Poor Prognosis In Patients With Symptomatic Waldenstrom’s Macroglobulinemia (2013) (2)
- High C-Terminal Cross-Linking Telopeptide of Collagen Type-I (CTX) Predicts for Poor Overall Survival in Patients with Multiple Myeloma Who Receive Frontline Therapy with Immunomodulatory Drugs (IMiDs) but Not with Bortezomib-Based Regimens (2012) (2)
- PS1349 UPDATED RISK STRATIFICATION MODEL FOR SMOLDERING MULTIPLE MYELOMA (SMM) INCORPORATING THE REVISED IMWG DIAGNOSTIC CRITERIA (2019) (2)
- Significant Improvement of the Survival of Patients with Multiple Myeloma Presenting with Severe Renal Impairment After the Introduction of Novel Agents (2012) (2)
- Chromosome 1q21 aberrations identify ultra high‐risk myeloma with prognostic and clinical implications (2022) (2)
- Elevated Serum Levels Of Von Willebrand Factor (vWF) Predict For Early Death and Shorter Survival In Patients With Primary Systemic Light Chain (AL) Amyloidosis Independently Of Cardiac Biomarkers (2013) (2)
- The International Prognostic Scoring System for Waldestrom’s Macroglobulinemia (ISSWM) Is Applicable in Patients Treated with Rituximab-Based Regimens. (2007) (2)
- Validation of the Novel Criteria for the Definition of Symptomatic Myeloma: A Single Center Experience in 216 Patients with the Previous Diagnosis of Asymptomatic Disease (2015) (2)
- Validation Of Criteria For Renal Response In Patients With Multiple Myeloma (MM) Who Present With Severe Renal Dysfunction (2013) (2)
- Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis (2022) (2)
- Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study “REBUILD” (2022) (2)
- Thalidomide for myeloma: still here? (2018) (2)
- High dose therapy for light chain amyloidosis: Can we reduce treatment related mortality further? (2008) (2)
- Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) As a Biomarker of Renal Outcomes in AL Amyloidosis (2020) (2)
- Estimated Glomerular Filtration Rate Calculated By The CKD-EPI Formula Has Improved Prognostic Ability Over MDRD Formula In Patients With Newly Diagnosed, Symptomatic, Multiple Myeloma: Analysis In 1937 Patients (2013) (2)
- Bone Remodeling in Patients with Relapsed/Refractory Multiple Myeloma Who Receive Lenalidomide-Based Regimens. (2007) (2)
- Diagnostic and Prognostic Value of non-LGE Cardiac Magnetic Resonance Parameters in Cardiac Amyloidosis. (2022) (2)
- Cardiac and Renal Complications of Carfilzomib Therapy in Patients with Multiple Myeloma (2016) (2)
- VWF, WM, and angiogenesis: is there a link? (2012) (2)
- Toll-Like Receptor Activation Promotes Multiple Myeloma Cell Growth and Survival By Suppression Of Endoplasmic Reticulum Stress Factor CHOP (2013) (2)
- OAB-034: Evaluating the impact of cytogenetic abnormalities on treatment outcomes in patients with AL amyloidosis: subanalyses from the ANDROMEDA study (2021) (2)
- The Utility of Non-LGE Cardiac Magnetic Resonance Imaging Parameters in the Diagnosis of Cardiac Amyloidosis. (2021) (2)
- Health‐related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study (2022) (2)
- IgD Myeloma: Clinical Features and Outcome In The Era Of Novel Agents (2013) (2)
- Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis (2022) (2)
- Real‐world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco‐Israeli collaborative myeloma working group (2020) (2)
- Prognostication of the high-risk WM patient. (2011) (2)
- Low circulating mannan-binding lectin levels correlate with increased frequency and severity of febrile episodes in myeloma patients who undergo ASCT and do not receive antibiotic prophylaxis (2017) (2)
- Liver and Gastrointestinal Involvement: Update. (2020) (2)
- Ibrutinib for rituximab-refractory Waldenström macro-globulinemia (2017) (2)
- Evolving chemotherapy options for the treatment of myeloma kidney: a 40-year perspective. (2012) (2)
- The Clinical Significance of a Novel microRNA Signature in Multiple Myeloma (2019) (1)
- Preclinical Studies of Salinomycin In Multiple Myeloma (MM) Models: Targeting of Side Population (SP) Cells In the Context of Tumor – Microenvironment Interactions. (2010) (1)
- Clinical Impact of an Early Response and of Early Initiation of Salvage Therapy in Patients with Systemic Light Chain (AL) Amyloidosis (2019) (1)
- Cardiopulmonary Exercise Physiology in AL Amyloidosis Patients with Cardiac Involvement and Its Association with Cardiac Imaging Parameters (2022) (1)
- No Significant Improvement In the Outcome of Patients with Waldenström's Macroglobulinemia Treated Over the Last 25 Years (2010) (1)
- Primary Treatment of Light Chain (AL) Amyloidosis With Bortezomib, Lenalidomide and Dexamethasone (VRD) or with Bortezomib, Cyclophosphamide and Dexamethasone (VCD/CyBorD): efficacy and toxicity (2018) (1)
- Functional Cure, Defined As PFS of More Than 7 Years, Is Achieved in 9% of Myeloma Patients in the Era of Conventional Chemotherapy and of First-Generation Novel Anti-Myeloma Agents; A Single-Center Experience over 20-Year Period (2018) (1)
- The Genomic and Transcriptomic Landscape of Double-Refractory Multiple Myeloma (2019) (1)
- Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study (2023) (1)
- Mineralocorticoid receptor signaling is implicated in carfilzomib-induced increase in blood pressure (2021) (1)
- Comparison of Proteasome Inhibitors-Induced Cardiotoxicity (carfilzomib vs. bortezomib): Insights into the Molecular Mechanisms (2017) (1)
- Pomalidomide with Low Dose Dexamethasone Is Effective Irrespective of Primary or Secondary Resistance to Lenalidomide but the IMiD-Free Interval Is Important (2016) (1)
- Monoclonal antibody-based therapies for Waldenström's macroglobulinemia (2022) (1)
- Daratumumab Monotherapy in Previously Untreated High-Risk Patients with Stage 3B Light Chain (AL) Amyloidosis: A Phase II Multicenter Study By European Myeloma Network (EMN) (2019) (1)
- Prospective Evaluation of the Risk of Thromboembolic Complications in Patients Treated with Lenalidomide-based Therapy and Genetic Associations (2011) (1)
- Vascular Cell Adhesion Molecule-1 Is An Independent Prognostic Factor For Newly-Diagnosed Patients With Multiple Myeloma; Reductions Post VD and Rd In Myeloma Patients At First Relapse (2013) (1)
- T Cell Immunoprofiling of Patients with Relapsed and/or Refractory Myeloma Who Receive Daratumumab Monotherapy: Longitudinal Analysis during 7 Cycle Follow-up of the Rebuild Phase 2 Study (2020) (1)
- Metformin Restores AMPK Alpha-Mediated Autophagy and Prevents Carfilzomib-Induced Cardiotoxicity In Vivo (2018) (1)
- Real-World Prospective Evaluation of Different Geriatric Assessment Tools in Unselected Elderly Patients with Symptomatic Myeloma (2015) (1)
- Bone marrow biopsy in low-risk MGUS patients reveals a novel MGUS-like Smoldering multiple myeloma risk group (2019) (1)
- Incidence of Skeletal-Related Events at Diagnosis and at the Time of First Relapse in 463 Patients with Multiple Myeloma Who Received First Line Treatment in a Single Center (2019) (1)
- The Transcriptional Signature of Kinases Inhibited by the Multi-Targeted Kinase Inhibitor AS703569 Is Associated with Clinical Outcome in Multiple Myeloma (MM): Anti-MM Activity of AS703569 in Preclinical Studies. (2009) (1)
- Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Cystatin-C Are Sensitive Markers of Renal Injury in Patients with Multiple Myeloma, (2011) (1)
- Pulmonary Function Tests Reveal Unrecognized Lung Dysfunction and Have Independent Prognostic Significance in Patients with Systemic AL Amyloidosis (2019) (1)
- Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma: Prognostic and More. (2022) (1)
- EFFECT OF DARATUMUMAB, BORTEZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE ON CARDIAC FUNCTION AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH NEWLY-DIAGNOSED AL AMYLOIDOSIS WITH CARDIAC INVOLVEMENT: RESULTS FROM THE PHASE 3 ANDROMEDA STUDY (2021) (1)
- Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) Is Able to Distinguish Diffuse from Normal MRI Pattern of Marrow Involvement in Patients with Multiple Myeloma (2014) (1)
- Lenalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma; Dosing of Lenalidomide According to Renal Function and Effect On Renal Impairment. (2009) (1)
- Utilization and tolerance of beta-blockers among patients with AL amyloidosis (2021) (1)
- Increased Levels of Circulating Plasma Cells in Patients with Newly Diagnosed Multiple Myeloma Are Independently Associated with Poor Prognosis (2022) (1)
- A Revised Staging System for Waldenström's Macroglobulinemia (2017) (1)
- macroglobulinemia (WM) and related disorders: IWWM-7 consensus Treatment recommendations for patients with Waldenström (2014) (1)
- Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Is a Renal Biomarker with Potential Clinical Applications in Monoclonal Gammopathy of Renal Significance (MGRS) (2019) (1)
- Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction (2020) (1)
- Phase I/II Study of Lenalidomide, Intermediate Dose Dexamethasone and Low Dose Cyclophosphamide (RDC) for the Treatment of Patients with Primary Systemic Amyloidosis (AL). (2008) (1)
- Carcinomatous meningitis from transitional cell carcinoma of the urinary bladder. (2011) (1)
- Changing Patterns of Symptomatic Myeloma after the Implementation of the 2014 IMWG Diagnostic Criteria and Reduced Early Mortality (2021) (1)
- The Finding of Del 17p in Marrow Plasma Cells from Patients with Light-Chain Amyloidosis (AL) May Confer a Worse Prognosis (2015) (1)
- Evaluation of Efficacy and Immune Modulation Associated with the Addition of IMiDs to Daratumumab Backbone in Patients Refractory to Both Drug Classes (2021) (1)
- The Impact of Different Pre-Transplant Regimens Including Novel Agents On Peripheral Blood Mobilization, Harvest, Response and Survival in Patients Undergoing ASCT for Multiple Myeloma. A Single-Center Experience in 210 Patients. (2009) (1)
- Reply to S. Girnius et al. (2013) (1)
- High Levels of Periostin in Patients with Multiple Myeloma Correlate with Low Bone Formation, Increased Fracture Rate and Diffuse MRI Pattern; Implications Into the Biology of Myeloma Bone Disease (2012) (1)
- The Chronic Kidney Disease-Epidemiology Collaboration-Cystatin C (CKD-EPI-CysC) Equation Has an Independent Prognostic Value for Overall Survival in Newly-Diagnosed Patients with Symptomatic Multiple Myeloma: Comparison with 3 Other Equations for GFR Estimation (2012) (1)
- Outcomes of Patients with t(11;14) Multiple Myeloma: An International Myeloma Working Group Multicenter Study (2019) (1)
- Diagnostics in Waldenström’s macroglobulinemia: a consensus statement of the European Consortium for Waldenström’s Macroglobulinemia (2022) (1)
- Short Daratumumab Consolidation in Patients with AL Amyloidosis or Lcdd Improves Complete Response Rates and Modifies Bone Marrow Microenvironment (2020) (1)
- Indirubins: A Potential Therapeutic Target in Multiple Myeloma (2016) (1)
- Immune Checkpoint Inhibitors’ Associated Renal Toxicity: A Series of 12 Cases (2022) (1)
- Determining patterns of vascular function and structure in wild-type transthyretin cardiac amyloidosis. A comparative study. (2022) (1)
- Bortezomib, Dexamethasone and Rituximab in Newly Diagnosed Patients with WaldenströM's Macroglobulinemia: Final Analysis of a Phase 2 Study after a Minimum Follow up of 6 Years (2016) (1)
- Natural History of Skeletal Related Events in Patients with Multiple Myeloma Who Received First- and Second- Line Therapy with Novel Agents: Results from a Single Center Analysis in 620 Patients (2019) (1)
- A 50-Year-Long Study of Waldenström Macroglobulinemia. (2019) (1)
- Cardiac mechanics in response to proteasome inhibition: a prospective study. (2022) (1)
- Carfilzomib-Induced Hypertension Is Mediated By Ion Channel Dysregulation in the Kidneys; The Potent Role of AMP-Activated Kinase α (2020) (1)
- Targeting the Clonogenic Side Population of Multiple Myeloma by Immunomodulatory Drugs (IMiDs) in the Context of Stromal Cell Microenvironment: Pathophysiologic and Clinical Implications. (2009) (1)
- Osteonecrosis of the jaw (ONJ) in patients with prostate (PC) or breast (BC) cancer treated with bisphosphonates: Study of the effect of the application of preventive measures (2008) (1)
- Longitudinal T Cell Immunoprofiling of Patients with Relapsed and/or Refractory Myeloma Who Receive Daratumumab Monotherapy: A Subanalysis of a Phase 2 Study (the REBUILD Study) (2019) (1)
- Variant transthyretin amyloidosis (ATTRv) polyneuropathy in Greece: a broad overview with a focus on non-endemic unexplored regions of the country (2021) (1)
- A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Daratumumab, Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (2022) (1)
- Circulating Periostin Is Elevated in Patients with Multiple Myeloma and Correlates with Advanced Disease Features and High Bone Resorption (2011) (1)
- OAB-038: Graded cardiac response criteria for AL amyloidosis: the impact of depth of cardiac response on survival (2021) (1)
- The Administration of Bortezomib, Dexamethasone and Thalidomide (VTD) after ASCT in Myeloma Patients Who Do Not Receive Bisphosphonates Normalizes sRANKL, Dickkopf-1 and Improves Abnormal Osteoclast Function and Impaired Angiogenesis. (2008) (1)
- Increased Expression of Cyclin-D1 on Trephine Bone Marrow Biopsies Independently Predicts for Shorter Overall Survival In Patients with Multiple Myeloma Treated with Novel Agents (2010) (1)
- Flow-Mediated Dilatation (FMD) and Aortic Blood Pressure May Predict Cardiovascular Adverse Events During Carfilzomib Therapy: A Prospective Study in Relapsed/Refractory Multiple Myeloma Patients (2019) (1)
- Dickkopf-1 and sclerostin in different phases of multiple myeloma; The effect of lenalidomide and dexamethasone treatment with or without bortezomib (2011) (1)
- Newly Diagnosed Multiple Myeloma Patients with Skeletal-Related Events and Abnormal MRI Pattern Have Poor Survival Outcomes: A Prospective Study on 370 Patients (2022) (1)
- Renal pathology in patients with monoclonal gammopathy or multiple myeloma: monoclonal immunoglobulins are not always the cause (2019) (1)
- Multiple Myeloma Patients ≤40 Years Of Age: Clinical Characteristics and Outcome In The Era Of Novel Agents (2013) (1)
- Outcomes of Primary Systemic Light Chain (AL) Amyloidosis in Patients Treated Upfront with Novel Agents and the Importance of Risk Adapted Treatment Strategies (2012) (1)
- The Ratio of Angiopoietin-1 to Angiopoietin-2 Is Reduced and Predicts Independently for Survival in Newly Diagnosed Patients with Multiple Myeloma. (2007) (1)
- SPOTLIGHT REVIEW Treatment of plasma cell dyscrasias with lenalidomide (2008) (1)
- Efficacy and Safety of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment or on Dialysis: Final Analysis of the Phase 2 Dare Study (2021) (1)
- Series MULTIPLE MYELOMA : FROM THE BENCH TO BEDSIDE Treatment options for relapsed and refractory multiple myeloma (2015) (1)
- Patient-reported outcomes (PROs) with ibrutinib-rituximab in Waldenström macroglobulinemia (WM): Results from iNNOVATE. (2019) (1)
- Protective Effects of Daratumumab on Carfilzomib-Related Cardiac Dysfunction in Patients with Relapsed Multiple Myeloma: Results from an Observational Study (2020) (1)
- Monoclonal Gammopathy of Thrombotic Significance (2023) (1)
- Acalabrutinib in Patients (pts) with Waldenström Macroglobulinemia (WM): NHL‐224 (2018) (1)
- Brain metastases as isolated site of relapse in patients with epithelial ovarian cancer previously treated with platinum and paclitaxel-based chemotherapy (2006) (1)
- Characteristics and Clinical Course of Myeloma in Patients 40 Years of Age or Younger: A Study of the Greek Myeloma Study Group (2011) (1)
- Safety and Efficacy of Daratumumab with Ixazomib and Dexamethasone in Patients with One Prior Lenalidomide-Based Regimen: Outcomes of the Phase 2 Daria Study (2021) (1)
- Response of an oncology unit in the midst of the COVID-19 outbreak (2020) (1)
- High Frequency of Monoclonal Immunoglobulins Exhibiting Natural Autoantibody-Like Activity in Patients with Multiple Myeloma and Waldenström Macroglobulinemia (2011) (1)
- Peripheral vascular involvement in transthyretin cardiac amyloidosis. A comparative analysis with AL amyloidosis (2021) (0)
- Primary Systemic Amyloidosis (2018) (0)
- P-148: Second booster BNT162b2 restores SARS-CoV-2 humoral response in patients with multiple myeloma, except for those under treatment with anti-BCMA agents (2022) (0)
- Amplification of 1q21 Is Associated with Other High Risk Cytogenetic Abnormalities and Has No Independent Prognostic Significance in Patients Treated with Novel Agents (2014) (0)
- OAB-036: Graded renal response criteria and revised renal progression criteria for light chain (AL) amyloidosis (2021) (0)
- The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018 (2023) (0)
- Light Chain Deposition Disease: First Analysis of an International Study in 359 Patients (2020) (0)
- Increased Levels of Serum Tissue Inhibitor of Metalloproteinase-1 Correlate with Advanced Stage, Increased Bone Resorption, Lytic Bone Disease and Poor Survival in Newly-Diagnosed Myeloma Patients (2008) (0)
- Immunoexpression of Macrophage Inflammatory Protein-1 Alpha on Bone Marrow Trephine Biopsies Correlates with the Extent of Bone Disease in Newly Diagnosed Patients with Multiple Myeloma (2008) (0)
- Real World Efficacy and Toxicity of Selinexor: Importance of Dose Intensity and Post Progression Outcomes (2022) (0)
- Antibacterial Prophylaxis Reduces the Incidence of Neutropenic Fever and the Rate of Infections in Patients with Multiple Myeloma Who Undergo An Autologous Stem Cell Transplantation. (2009) (0)
- Editorial: Exploiting the Immune System to Treat Multiple Myeloma: From Transplantation to Novel Treatment Approaches (2020) (0)
- Lenalidomide with Low or Intermediate Dose Dexamethasone in Patients with Relapsed or Refractory Myeloma (2012) (0)
- Poor Neutralizing Antibody Responses in Patients with CLL, NHL and HL after Vaccination Against Sars-Cov-2; A Prospective Study in 132 Patients (2021) (0)
- P-161: Oral antivirals ritonavir-nirmatrelvir and molnupiravir are highly effective in patients with multiple myeloma and COVID-19; a singlecenter, prospective study (2022) (0)
- Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events (2017) (0)
- miRNA-seq and clinical evaluation in multiple myeloma: miR-181a overexpression predicts short-term disease progression and poor post-treatment outcome (2021) (0)
- The Bone Marrow Microenvironment and Tumor Cells Interactions in Waldenström’s Macroglobulinemia (2017) (0)
- Prognostic Significance of Circulating Plasma Cells Detected By Next Generation Flow Cytometry in Light (AL) Chain Amyloidosis (2022) (0)
- Patient-Reported Outcomes from Patients with Waldenstrom Macroglobulinemia Treated with Ibrutinib-Rituximab: Results from iNNOVATE Study (2019) (0)
- The role of ibrutinib in Waldenström macroglobulinemia (2018) (0)
- Author's reply: To PMID 23705905. (2014) (0)
- P-209: High response rates with IMiD retreatment post anti-CD38 exposure in patients with Multiple Myeloma (2021) (0)
- Antibody Response to COVID-19 mRNA Vaccine in Patients with Multiple Myeloma and Waldenstrom's Macroglobulinemia after Primary Immunization and Booster: Reactivity to the Sars-Cov-2 WT Virus, Delta and Omicron Variants (2022) (0)
- Outcomes for patients with systemic light chain amyloidosis and Mayo stage 3B disease. (2023) (0)
- Increased Semaphorin-4D and Plexin-B1 Levels in Multiple Myeloma Patients May Contribute to Osteolytic Bone Disease (2017) (0)
- Circulating Adamts-13 Is Reduced in Patients with Waldenstrom's Macroglobulinemia and Is Associated with Increased IgM Levels and Features of the Disease but Not with the Increased Levels of Von Willebrand Factor (2014) (0)
- Lenalidomide, Adriamycin, and Dexamethasone (RAD) As Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Eligible for Autologous Transplantation (ASCT): A Phase 2 Study from the Greek Myeloma Study Group (2016) (0)
- Monoclonal Antibodies for Waldenström Macroglobulinemia. (2018) (0)
- Impact of Daratumumab Monotherapy on Bone Metabolism Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least Two Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor: Outcomes of the Phase 2 Rebuild Study (2021) (0)
- Reduced Repair Efficiency Correlates with Increased Cellular Chemosensitivity and Better Response to High Dose Melphalan of Patients with Multiple Myeloma (2010) (0)
- Genomic Profiling of Smoldering Multiple Myeloma Classifies Molecular Groups with Distinct Pathogenic Phenotypes and Clinical Outcomes (2021) (0)
- Mobilization of Autologous Peripheral Blood Stem Cells with Spectra Optia v5.0: A Single Center Experience with An Automatic Interface-Controlled Apheresis System (2011) (0)
- P-059: miRNA profiling of CD138+ plasma cells identifies miR-181a-5p overexpression as independent predictor of short-term progression and poor treatment outcome in multiple myeloma (2021) (0)
- MULTIPLE MYELOMA: FROM THE BENCH TO BEDSIDE Treatment options for relapsed and refractory multiple myeloma (2015) (0)
- Prospective Evaluation of Blood Pressure Monitoring and Baroreceptor Reflex Sensitivity (BRS) in Patients with AL Amyloidosis: Prognostic and Pathophysiologic Implications (2015) (0)
- Temporal Dynamics of Tumor-Microenvironment Interaction and Treatment Responses Revealed through Time-Lapse Compartment-Specific Bioluminescence Imaging: Translational implications (2014) (0)
- MM-252: Aberrant Plasma Cells in the Apheresis Product as a Prognostic Factor for Minimal Residual Disease Negativity After Transplant in Newly Diagnosed Myeloma Patients (2020) (0)
- Angiogenic Cytokines Are Increased in the Serum of Patients with Waldenastrom’s Macroglobulinemia (WM): Correlations with Clinical Data. (2005) (0)
- A014 High Serum TIMP-1 Correlates with Advanced Myeloma and Poor Survival (2009) (0)
- Competing Risk Survival Analysis In Patients With Symptomatic Waldenström’s Macroglobulinemia (WM): Disease Unrelated Mortality Accounts For Differences In Survival In Patients >75 Years (2013) (0)
- Phase 2 Study of Daratumumab (DARA) Plus Bortezomib, Cyclophosphamide, and Dexamethasone (D-VCd) in Patients with Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis: Aquarius (2022) (0)
- Tubular Damage Is Present In Patients With MGUS and Asymptomatic Multiple Myeloma Even In The Absence Of Impaired Estimated Glomerular Filtration Rate; Alterations Of Neutrophil Gelatinase-Associated Lipocalin and Cystatin-C In Myeloma Patients Post IMiD- and Bortezomib-Based Regimens (2013) (0)
- Cardiac amyloidosis presenting with coronary artery embolization. (2021) (0)
- Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab‐based quadruplets: A multicenter study by the Greek myeloma study group (2022) (0)
- Highly Sensitive Detection Method of CXCR4 Tumor Hotspot Mutations by Drop-off Droplet Digital PCR in patients with IgM-Monoclonal gammopathies. (2023) (0)
- High Bone Turnover Is Present in Patients with Primary Systemic (AL) Amyloidosis and Increased Osteoprotegerin Identifies Patients with Poor Survival within Mayo Stage 1 Disease (2014) (0)
- Strong Correlation Between Angiogenesis and Macrophage Counts in Waldenstrom’s Macroglobulinemia: Implications into the Biology of the Disease (2008) (0)
- Inter and Intra-Clonal Heterogeneity in Multiple Myeloma and Waldenstrom Macroglobulinemia (2014) (0)
- Outcomes of Consecutive Patients With Newly Diagnosed Myeloma Requiring Dialysis: Dialysis Independence is Associated with Rapid Myeloma Response and Predicts for Longer Survival (2017) (0)
- Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma who Are Treated with Bortezomib-Based Therapy (2019) (0)
- Peripheral blood immune profiling of multiple myeloma patients at diagnosis: correlations with circulating plasma cells (2020) (0)
- Translating Findings of Proteasome Inhibitors Effects from the in Vivo Drosophila Experimental Model to Humans: The Paradigm of the Molecular-Cellular Responses to Bortezomib and Carfilzomib (2014) (0)
- Osteopontin Predicts for Survival and Cystatin C-Based Estimated GFR Predicts for Renal Response to Therapy in Patients with Primary Systemic Amyloidosis (2008) (0)
- P-127: Patients with Multiple Myeloma on treatment with Anti-CD38 or Anti-BCMA agents have a suboptimal humoral response following COVID-19 vaccination (2021) (0)
- Low Circulating Mannan-Binding Leptin Levels Correlate with Increased Number of Febrile Episodes in Myeloma Patients Who Undergo High Dose Melphalan with Autologous Hematopoietic Stem Cell Transplantation and Do Not Receive Antibiotic Prophylaxis (2011) (0)
- De Novo AL Amyloidosis in Renal Allograft and Anti-CD38 Monoclonal Antibody Treatment (2021) (0)
- Nephrotoxicity in patients with cancer treated with immune checkpoint inhibitors. (2021) (0)
- Symptomatic Waldenstrom’s Macroglobulinemia (WM) in Young Patients: Disease Characteristics and Outcome. (2007) (0)
- High-dimensional Clonal Heterogeneity and Immune Landscape in Multiple Myeloma (2019) (0)
- Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib‐dexamethasone versus physician's choice (2023) (0)
- Al amyloidosis with cardiac involvement: cardiotoxicity of aggregation prone peptides deriving from variable domains of immunoglobulin light chains (2020) (0)
- Carfilzomib Induces Acute Endothelial Dysfunction Which Correlates with the Occurrence of Cardiovascular Events (2018) (0)
- Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study (2023) (0)
- Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemia. (2023) (0)
- Newly Diagnosed Multiple Myeloma is Associated with Hypercoagulability and High Risk of VTE The ROADMAP Study (2016) (0)
- Patients with Multiple Myeloma on Anti-CD38 or Anti-BCMA Based Regimens and Patients with Waldenstrom's Macroglobulinemia Under Rituximab or BTK Inhibitors Have a Poor Humoral Response Following COVID-19 Vaccination (2021) (0)
- Real-world Data on Incidence, Clinical Characteristics and Outcome of Patients with Macrofocal Multiple Myeloma in the Novel Therapeutic Era: A study of the Greco-Israeli Collaborative Myeloma Working Group (2019) (0)
- Contents Vol. 73, 2007 (2008) (0)
- Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Newly Diagnosed Chemotherapy Naïve Patients with Multiple Myeloma at Risk for Cancer‐Associated Thrombosis. The Observational ROADMAT‐CAT‐MM Study: MM‐021 (2018) (0)
- MM-408: The Assessment of Stem Cell Graft Contamination via Next-Generation Flow Cytometry Serves as a Negative Predictor for Deep Remissions Post-Autologous Stem Cell Transplantation in Multiple Myeloma (2021) (0)
- Effect of Amp5q31 and Del12p13 on Survival of Patients with Multiple Myeloma Treated with Novel Agent-Based Regimens: A Single Center Experience on 172 Patients (2011) (0)
- Waldenström Macroglobulinemia: Lessons Learned from Basic and Clinical Research. (2018) (0)
- Renal Outcomes in Patients with AL Amyloidosis: Evaluation of Prognostic Factors and Impact of Therapy with Novel Agents (2014) (0)
- Ocular Adverse Events in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in a Phase 1/2 Trial (2022) (0)
- Synergistic Effect of Carfilzomib and Metformin in Vascular Plasticity (2019) (0)
- A425 EGFR Based on Cystatin-C, Creatinine, and Age Is Independently Associated with Survival in Myeloma (2009) (0)
- Single Cell Analysis of MYD88 L265P and MYD88 WT Waldenström Macroglobulinemia Patients (2021) (0)
- Development of New Treatment Strategies Targeting Clonogenic and Tumorigenic Myeloma Side Population. (2010) (0)
- The nephrotoxicity of bortezomib: did we miss a complication after 20 years of use and multiple landmark trials? (2023) (0)
- Abstract A237: The transcriptional signature of kinases inhibited by the multitargeted kinase inhibitor AS703569 is associated with inferior clinical outcome in multiple myeloma (MM), with promising anti‐MM activity of AS703569 demonstrated in preclinical studies in vitro and in vivo (2009) (0)
- Preserved Levels Of Uninvolved Immunoglobulins Are Associated With Better Overall Survival In Patients With Multiple Myeloma Independently Of Disease Burden: A Role For The Immune System? (2013) (0)
- PF564 OUTCOMES OF PATIENTS WITH T(11;14) MULTIPLE MYELOMA: AN INTERNATIONAL MYELOMA WORKING GROUP MULTICENTER STUDY (2019) (0)
- Antibody Response after Vaccination for Sars-Cov-2 in Patients with AL Amyloidosis and the Impact of Therapy (2021) (0)
- Myeloma: Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (2013) (0)
- A013 Immunoexpression of MIP-1alpha on Marrow Biopsies Correlates with the Extent of Myeloma Bone Disease (2009) (0)
- IMiD Retreatment in Patients Refractory to Both an IMiD and an Anti-CD38 Antibody Induces Significant Response Rates Post Anti-CD38 Exposure (2020) (0)
- Macrophage Inflammatory Protein-1 alpha (MIP-1α) Is Increased in Patients with Waldenstrom’s Macroglobulinemia and Correlates with the Severity of Disease. (2005) (0)
- A166 VMP in Renally Impaired Newly Diagnosed MM Patients: Cohort Analysis of the VISTA Study (2009) (0)
- Diffuse MRI Marrow Pattern Correlates with Increased Angiogenesis, Advanced Disease Features and Poor Prognosis in Newly-Diagnosed Patients with Multiple Myeloma Treated with Novel Agents. (2009) (0)
- High Frequency of CNS Involvement in Transformed Waldenström Macroglobulinemia (2021) (0)
- Management and Outcomes of Anti-CD38 Refractory Myeloma Patients: The Impact of Retreatment and of Subsequent Therapies (2022) (0)
- Screening for Gaucher disease in patients with plasma cell dyscrasias (2019) (0)
- Investigating the impact of aging and hyperlipidaemia on metformin cardioprotection against carfilzomib-induced cardiotoxicity in vivo (2020) (0)
- Genetic Variations In TLR-4/TIRAP Genes Influence Response To IMiDs-Based Regimens and Conventional Chemotherapy In Patients With Multiple Myeloma (2013) (0)
- Thalidomide Based Regimens (TBR) for Relapsed/Refractory Multiple Myeloma Patients: Long Term Follow Up, Unmaintained Remissions and Disease Control after Subsequent Treatments. (2007) (0)
- Impact of cytogenetic abnormalities on treatment outcomes in patients with amyloid light-chain amyloidosis: subanalyses from the ANDROMEDA study. (2023) (0)
- Sclerostin Remains Elevated Even in the Plateau Phase of Myeloma Patients: Implications into the Pathogenesis of Osteoblast Dysfunction of Multiple Myeloma (2015) (0)
- Outcomes of Newly Diagnosed Myeloma Patients Requiring Dialysis: Dialysis Independence Is Associated with Rapid Myeloma Response and Predicts for Longer Survival (2016) (0)
- Immunomodulatory Agents and Proteasome Inhibitors in Waldenstrom’s Macroglobulinemia (2017) (0)
- A Phase 1/2 Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, PK and Efficacy of ZN-d5, a Novel BCL-2 Inhibitor, for Treatment of Subjects with Relapsed/Refractory AL Amyloidosis (2022) (0)
- Carfilzomib-Induced Cardiotoxicity in an In Vivo Model of Aging (2020) (0)
- Assessing the prognostic utility of hematologic response for overall survival in patients with newly diagnosed AL amyloidosis: results of a meta-analysis. (2023) (0)
- Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study (2018) (0)
- Daratumumab for Immunoglobulin Light Chain Amyloidosis (2021) (0)
- Ibrutinib/Rituximab versus Placebo/Rituximab: A Randomized, Phase 3 Trial in Waldenström’s Macroglobulinemia (iNNOVATE): NHL‐191 (2018) (0)
- Recent Data Supporting Novel Management Strategies for Patients With Multiple Myeloma. (2016) (0)
- Venetoclax in Relapse/Refractory AL Amyloidosis—A Multicenter International Retrospective Real-World Study (2023) (0)
- Longitudinal Evaluation of Minimal Residual Disease in Patients with Multiple Myeloma who Achieve Complete Response After First Line Therapy (2019) (0)
- COVID-19 mRNA vaccine-induced adverse effects: unwinding the unknowns (2022) (0)
- SUBCUTANEOUS DARATUMUMAB + BORTEZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE (VCD) IN PATIENTS WITH NEWLY DIAGNOSED LIGHT CHAIN (AL) AMYLOIDOSIS: UPDATED RESULTS FROM THE PHASE 3 ANDROMEDA STUDY (2021) (0)
- Efficacy and Tolerability of Daratumumab with Ixazomib and Dexamethasone in Patients with One Prior Lenalidomide-Based Regimen: Preliminary Results of the Phase 2 Daria Study (2020) (0)
- Treatment of Multiple Myeloma and Related Disorders: DIAGNOSIS, RISK-STRATIFICATION, AND MANAGEMENT OF SOLITARY PLASMACYTOMA (2008) (0)
- The Combination of Bortezomib and Lenalidomide (VR) Consolidation Post-ASCT, in the Absence of Dexamethasone and Bisphosphonates, Improves Response Rates and Bone Metabolism in Newly Diagnosed Patients with Multiple Myeloma (2014) (0)
- Approach to Contemporary Risk Assessment, Prevention and Management of Thrombotic Complications in Multiple Myeloma (2022) (0)
- P-169: Bendamustine rituximab primary therapy for Waldenström Macroglobulinemia: an international, multicenter collaborative study (2022) (0)
- Systemic Diseases (2010) (0)
- Patients with Multiple Myeloma and Prior COVID-19 Have Superior Antibody Responses Against Sars-Cov-2 Compared with Fully Vaccinated Myeloma Patients with the BNT162b2 Vaccine (2021) (0)
- Investigation of the cardiotoxicity of full-length light chains derived from patients with cardiac light chain amyloidosis, multiple myeloma and monoclonal gammopathy of undetermined significance (2022) (0)
- Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis (2018) (0)
- Abstract 2004: Phenotypic and molecular characterization of inter- and intraclonal heterogeneity in multiple myeloma and Waldenstrom macroglobulinemia (2015) (0)
- Novel Anti-Myeloma Agents and Bone Metabolism: Implications in the Management of Myeloma Bone Disease (2009) (0)
- Dysfunctions of innate and adaptive immune tumor microenvironment in Waldenström macroglobulinemia (2022) (0)
- High dose melphalan in primary systemic amyloidosis: status quo? (2010) (0)
- Absence of Aberrant Plasma Cells in the Apheresis Product Predicts for Minimal Residual Disease Negativity after Autologous Transplantation in Myeloma Patients Who Receive First Line Therapy (2019) (0)
- Managing complications secondary to Waldenström’s macroglobulinemia (2021) (0)
- Deletion 17p in Unselected Newly Diagnosed Symptomatic Patients with Multiple Myeloma (2011) (0)
- Contents Vol. 72, 2007 (2008) (0)
- PS1378 AN EARLY, WITHIN THE FIRST MONTH, AND DEEP RESPONSE, SHOULD BE THE GOAL OF THERAPY IN AL AMYLOIDOSIS (2019) (0)
- Outcomes of Patients with AL Amyloidosis after Failure of Daratumumab-Based Therapy (2022) (0)
- Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA (2023) (0)
- P-249: Real world evidence and outcomes of patients who are exposed or refractory to lenalidomide at the time of first relapse: a Greek registry analysis (2022) (0)
- Bortezomib-Based Triplets Are Associated with a High Probability of Dialysis Independence and Rapid Renal Recovery in Newly Diagnosed Myeloma Patients with Severe Renal Failure or Those Requiring Dialysis (2015) (0)
- CLINICAL TRIALS OBSERVATIONS BDR in newly diagnosed patients with WM: fi nal analysis of a phase 2 study after a minimum follow-up of 6 years (2017) (0)
- Diffuse Pattern of Bone Marrow Involvement in MRI Is Associated with High Risk Cytogenetics and Poor Outcome in Newly Diagnosed, Symptomatic Patients with Multiple Myeloma, (2011) (0)
- The patient with myeloma (2018) (0)
- Chemotherapy with carboplatin - paclitaxel as the only adjuvant treatment in uterine papillary serous and clear cell carcinoma (2005) (0)
- Effect of Circulating CCL3, Which Is Produced by Malignant Cells of Waldenström's Macroglobulinemia, on Patients' Survival (2011) (0)
- A novel microrna signature with clinical significance in multiple myeloma (2020) (0)
- Circulating Adiponectin and Markers of Endothelial and Cardiovascular Dysfunction Correlate with Disease Burden in Newly Diagnosed Patients with Multiple Myeloma; Increase of Adiponectin after Bortezomib- and IMiD-Based Regimens (2016) (0)
- MM-468 Longitudinal Assessment of Minimal Residual Disease Dynamics in Patients With Multiple Myeloma who Achieve Complete Response after First Line Therapy. (2022) (0)
- Circulating Angiogenic Cytokines Are Elevated in Patients with Smoldering Myeloma; Implications Into Disease Biology (2011) (0)
- Upfront Treatment with Novel Agents Improves the Survival of Symptomatic Patients with Multiple Myeloma Who Are Older Than 65 Years (2010) (0)
- Hemodynamic, Functional and Structural Markers of Vascular Involvement in Primary Systemic Light Chain (AL) Amyloidosis (2014) (0)
- High Serum Levels of Angiogenic Cytokines in AL Amyloidosis Correlates with Disease Features. (2007) (0)
- Diffuse MRI Pattern of Marrow Infiltration Correlates with Suppressed Bone Formation and Increased Incidence of Vertebral Fractures in Multiple Myeloma. (2006) (0)
- Circulating Levels of Angiogenic Cytokines in Waldenstrom’s Macroglobulinemia: Clinical Correlations (2014) (0)
- Prior Lenalidomide Resistance and the Impact of IMiD-free Interval in Patients Treated with Pomalidomide and Dexamethasone (2017) (0)
- SP159OUTCOME OF PATIENTS WITH FIBRILARY GLOMERULONEPHRITIS : A SINGLE CENTER EXPERIENCE (2018) (0)
- PS1394 FLOW-MEDIATED DILATATION AND AORTIC BLOOD PRESSURE PREDICT CARDIOVASCULAR ADVERSE EVENTS DURING CARFILZOMIB TREATMENT: A PROSPECTIVE STUDY IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA (2019) (0)
- Extensive Bone Marrow Infiltration and Abnormal Free Light Chain Ratio Identifies Patients with Smoldering Myeloma At High Risk for Progression to Symptomatic Disease (2011) (0)
- Subject Index Vol. 72, 2007 (2008) (0)
- Growth Differentiation Factor 15 (GDF-15) Is a New Biomarker for Overall Survival and Renal Outcomes in Patients with Light Chain (AL) Amyloidosis (2017) (0)
- Newly Diagnosed Multiple Myeloma Is Associated with Enhanced TF Pathway Activation, Thrombin Generation and Increased Concentration of Procoagulant Microparticles (2015) (0)
- Short Progression Free Survival Predicts for Poor Overall Survival In Older Patients with Multiple Myeloma Treated Upfront with Novel Agent-Based Therapy (2010) (0)
- Health-Related Quality of Life and Symptoms Among Patients with Relapsed or Refractory AL Amyloidosis Treated with Ixazomib-Dexamethasone Versus Physician's Choice: Results from a Randomized Phase 3 Trial (2021) (0)
- Abstract 17312: Amyloid-β (1-40) and the Risk of Death from Cardiovascular Causes in Patients with Coronary Heart Disease (2014) (0)
- Laboratory Investigations and Findings: Hematological Abnormalities, Biochemical Investigations, Free Light and Heavy Chains (2017) (0)
- Analysis of Molecular-Cellular Responses to Proteasome Inhibitors in Multiple Myeloma Patients; A Translational Approach of Proteasome Inhibitors In Vivo Effects from the Drosophila Experimental Model to Humans (2015) (0)
- A136 Len/Dex ± Bortezomib for Advanced Myeloma According to Prior Neuropathy: The Impact of Cytogenetics (2009) (0)
- miRNA-seq identification and clinical validation of CD138+ and circulating miR-25 in treatment response of multiple myeloma (2023) (0)
- Primary Systemic Amyloidosis (AL) (2011) (0)
- OAB-036: The PANGEA model: dynamic modeling for personalized prediction of precursor disease progression to multiple myeloma (2022) (0)
- Prognostic Significance of Magnetic Resonance Imaging (MRI) of Bone Marrow (BM) in Patients with Multiple Myeloma (MM) Undergoing Treatment with High-Dose Melphalan (HDM) and Autologous Stem Cell Transplantation (ASCT). (2006) (0)
- Analysis of the genomic and transcriptomic landscape of chemoresistant multiple myeloma (2019) (0)
- Pulmonary function tests reveal unrecognised lung dysfunction and have independent prognostic significance in patients with systemic AL amyloidosis. (2022) (0)
- Clinical Characteristics and Outcomes of Myeloma Patients Exhibiting Translocation (14;16): An Ultra-High-Risk Group of Myeloma Patients (2017) (0)
- Subject Index Vol. 73, 2007 (2008) (0)
- The Genomic Landscape of Waldenström Macroglobulinemia Reveals Sustained Germinal Center Activity and Late-Developing Copy Number Aberrations (2021) (0)
- Mutation-dependent treatment approaches for patients with complex multiple myeloma (2021) (0)
- 5040 POSTER Recurrent or metastatic endometrial cancer: Prognostic factors after taxane-based systemic chemotherapy (2007) (0)
- Inhibition of c-Myc Expression and Function in Hematologic Malignancies (2011) (0)
- Cisplatin versus carboplatin-based chemotherapy in inoperable or recurrent urothelial carcinoma: A retrospective analysis. (2006) (0)
- PF614 PATIENT-REPORTED OUTCOMES FROM THE INNOVATE™ STUDY: RESULTS OF IBRUTINIB-RITUXIMAB IN WALDENSTRÖM MACROGLOBULINEMIA (WM) (2019) (0)
- Poster: MM-468 Longitudinal Assessment of Minimal Residual Disease Dynamics in Patients With Multiple Myeloma who Achieve Complete Response after First Line Therapy (2022) (0)
- Belantamab mafodotin induces immunogenic cell death within 24 h post‐administration in newly diagnosed multiple myeloma patients (2022) (0)
- Bone Marrow Biopsy May Be Required During the Initial Evaluation of Individuals with Asymptomatic Monoclonal Gammopathy (2011) (0)
- Pomalidomide-Dexamethasone Effectiveness in t(11;14) Positive Relapsed Multiple Myeloma in Real-World Setting (2021) (0)
- Survival until First Progression and Post First Progression Survival Equally Contribute to the Overall Survival of Myeloma Patients: Differences in Patients ≤65 Years of Age Compared to Patients >65 Years (2012) (0)
- High Circulating Vascular Endothelial Growth Factor Receptor-1 Correlates with Increased Microvessel Density and Inferior Survival in Newly-Diagnosed Patients with Multiple Myeloma Who Receive Frontline Therapy with Novel Agent-Based Regimens (2011) (0)
- Methyljasmonate, An Inhibitor of Glycolytic Energy Production, Displays Pre-Clinical Activity against Multiple Myeloma Cells. (2009) (0)
- Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma (2018) (0)
- Genomic Landscape of IgM MGUS and Asymptomatic Waldenström Macroglobulinemia Patients (2022) (0)
- Risk of Progression and Survival in Newly Diagnosed Multiple Myeloma Patients Non-Responsive to Bortezomib-Based Induction Therapy: an Observational Multicenter International Study (2014) (0)
- Heterogeneity of B cell lymphopoiesis in patients with premalignant and active myeloma (2023) (0)
- P-051: Sustained bone marrow and imaging MRD negativity as indicators to discontinue lenalidomide maintenance after ASCT; preliminary results of a single-center prospective cohort study (2022) (0)
- Evaluation of Immune Profile in Patients with Multiple Myeloma Using Cytof Technology (2014) (0)
- Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients (2021) (0)
- Progression Risk-Based Classification of Asymptomatic Waldenström Macroglobulinemia (2018) (0)
- How I use Bone Support (2015) (0)
- The Cancer-Related Circrna Cirs-7 (CDR1-AS) Is Differentially Expressed in CD138+ Cells of Patients with Plasma Cell Disorders and Predicts Unfavorable Overall Survival in Multiple Myeloma (2022) (0)
- Waldenström’s Macroglobulinemia Associated with Cryoglobulinemia: Pathogenetic, Clinical, and Therapeutic Aspects (2012) (0)
- Consolidation with a Short Course of Daratumumab Improves Complete Response Rates in Patients with AL Amyloidosis or Lcdd (2018) (0)
- RAD Regimen Increases Bone Formation and Reduces Bone Resorption and Angiogenesis in Patients with Newly Diagnosed Myeloma: Results of a Phase 2 Study (2017) (0)
- DIAGNOSTIC AND PROGNOSTIC VALUE OF NEWER CARDIAC MAGNETIC RESONANCE PARAMETERS IN PATIENTS WITH CARDIAC AMYLOIDOSIS (2023) (0)
- PS1393 PRIMARY TREATMENT OF LIGHT CHAIN (AL) AMYLOIDOSIS WITH BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE (VRD) (2019) (0)
- Translocation (14;16) Positive Multiple Myeloma: Clinical Features and Survival Outcomes of a High‐risk Population: MM‐257 (2018) (0)
- Clonal Heterogeneity and Immune Tumor Microenvironment in Waldenström Macroglobulinemia (2019) (0)
- B03: SKELETAL-RELATED EVENTS AND ABNORMAL MRI PATTERN AT DIAGNOSIS ARE ASSOCIATED WITH INFERIOR OVERALL SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (2022) (0)
- Blood transcriptomes of anti-SARS-CoV2 antibody positive healthy individuals with prior asymptomatic versus clinical infection (2021) (0)
- Real-World Data on Clinical Characteristics, Prognosis and Outcome of Primary Plasma Cell Leukemia: A Study of the Greek Myeloma Study Group in the Era of Novel Agents (2016) (0)
- Survivorship in WM: Identification of Factors Associated with Survival of More Than a Decade and with Early WM-Related Death (2016) (0)
- Clinical Characteristics and Outcome of Primary AL Amyloidosis in Greece. (2007) (0)
- P-009: Assessing the predictive utility of hematologic response for overall survival in patients with newly diagnosed AL amyloidosis: a systematic literature review and meta-analysis (2021) (0)
- Abstract 2259: Predictive modeling of smoldering multiple myeloma progression to multiple myeloma by continuous variable analysis (2022) (0)
- Evaluation of MET T1010I and MET rs40239 single-nucleotide polymorphisms in triple-negative breast cancer: a case–control study (2019) (0)
- Patterns of target organ amyloid deposition in patients with AL amyloidosis; role for diagnosis and prognosis. (2023) (0)
- Second Primary Malignancies and Disease Transformation in Newly Diagnosed Symptomatic Patients with Waldenstrom's Macroglobulinemia: An Analysis from the Greek Myeloma Study Group (2018) (0)
- Analysis of the genomic lanscape of multiple myeloma highlights novel candidate prognostic markers and disease subgroups (2017) (0)
- Elevated Involved Light Chains Discordant to the Increase of the Involved Heavy Chains Identifies a Subset of Multiple Myeloma Patients with Worse Outcome (2014) (0)
- Percentage of family history of cancer in patients with breast cancer: Is it changing with ethnicity? (2011) (0)
- High frequency of central nervous system involvement in transformed Waldenström macroglobulinemia (2022) (0)
- Abstract 12474: Amyloid-{beta} 1-40 as an Independent Cardiovascular Risk Factor: First Evidence in Patients With Cardiovascular Disease (2013) (0)
- Cardiovascular Toxicity of Proteasome Inhibitors: Underlying Mechanisms and Management Strategies (2023) (0)
- A Prospective Study and Identification of Genomewide Association Markers of Familial Predisposition to Plasma Cell Dyscrasias (2020) (0)
- Bortezomib and Lenalidomide (VR) Consolidation Post-ASCT without Dexamethasone and Bisphosphonates: Final Analysis of a Prospective Study (2017) (0)
- Toll-Like Receptor 4 Activation Promotes Multiple Myeloma Cell Growth and Survival Via Suppression of The Endoplasmic Reticulum Stress Factor Chop (2019) (0)
- Efficacy of Daratumumab Monotherapy on Bone Metabolism of Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results from the Phase 2 Rebuild Study (2020) (0)
- Ibrutinib/rituximab versus placebo/rituximab in Waldenstrom's Macroglobulinemia (WM): results of a randomized phase 3 trial (2018) (0)
- PATIENT‐REPORTED OUTCOMES (PROs) IN WALDENSTRÖM MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH IBRUTINIB‐RITUXIMAB IN THE INNOVATE STUDY (2019) (0)
- Waldenström macroglobulinemia whole genome reveals prolonged germinal center activity and late copy number aberrations (2022) (0)
- Dynamic contrast-enhanced MRI parameters correlate with angiopoietin-1/angiopoietin-2 ratio and high-risk features in patients with multiple myeloma (2015) (0)
- Increased Osteoprotegerin Levels in Response to Increased Bone Resorption in AL Amyloidosis: Comparisons with Bone Remodeling of Multiple Myeloma. (2007) (0)
- Primary plasma cell leukemia presenting as secondary pulmonary alveolar proteinosis (2020) (0)
- MM-167: Phenotypic and Prognostic Evaluation of Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma Detected with Next-Generation Flow Cytometry (NGF) (2020) (0)
- Increased levels of Vascular Cell Adhesion Molecule-1 (VCAM-1) and Inter-Cellular Adhesion Molecule-1 (ICAM-1) Correlate with Advanced Disease Features and Poor Survival in Newly Diagnosed Patients with Multiple Myeloma. Reduction Post-Bortezomib- and Lenalidomide-Based Regimens. (2009) (0)
- Prevalence of Monoclonal Gammopathy of Clinical Significance (MGCS) Among Patients with Monoclonal Gammopathies: Report from a Referral Center (2022) (0)
- Efficacy of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: An Interim Analysis of a Phase 2 Study (the DARE Study) (2019) (0)
- Bing Center for Waldenström’s macroglobulinemia update on plasma cell disorders (2008) (0)
- Myeloma Heterogeneity within Its Complex Immune Ecosystem (2019) (0)
- High-Dimensional Heterogeneity of Waldenström Macroglobulinemia within Its Immune Tumor Microenvironment (2019) (0)
- Impact of Bone Marrow Biopsy on Risk Stratification of Low-Risk IgG MGUS Patients (2017) (0)
- MM-039: Natural History of Skeletal-Related Events Among 620 Patients with Multiple Myeloma Who Received First- and Second-Line Therapy with Novel Agents: A Single-Center Analysis (2020) (0)
- Global deterioration of cardiovascular mechanics by carfilzomib treatment is associated with proteasome activity in patients with relapsed multiple myeloma (2021) (0)
- Synergistic Effect of Carfilzomib and Metformin in Vascular Plasticity; The Emerging Role of Autophagy (2019) (0)
- The proteasome inhibitor carfilzomib (Cfz) induces cardiotoxicity in vivo: molecular mechanisms and the cardioprotective effect of metformin (Met) (2018) (0)
- educational session Hematological malignancies (2006) (0)
- Serum Neutrophil Gelatinase-Associated Lipocalin Independently Predicts for Renal Response in Myeloma Patients with Severe Renal Impairment (2019) (0)
- P4787Investigating the molecular mechanisms of carfilzomib-induced cardiotoxicity and the emerging role of metformin as a prophylactic therapy (2018) (0)
- Vulnerability Variables Among Octogenarians Myeloma Patients: A Single-Center Analysis in 110 Patients (2017) (0)
- High Levels of Periostin in Patients with Multiple Myeloma Correlate with Low Bone Formation, Increased Fracture Rate and Diffuse MRI Pattern (2015) (0)
- HP57 : Peripheral nerve involvement in AL Amyloidosis : A long prospective follow up study (2022) (0)
- Characterization and clinical implications of peripheral arterial involvement in transthyretin cardiac amyloidosis cardiomyopathy (2020) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Efstathios Kastritis?
Efstathios Kastritis is affiliated with the following schools:
